Swiss Biotech Nouscom Raises $135 Million to Advance Experimental Cancer Prevention Vaccine

Swiss biotechnology company Nouscom has raised $135 million in an oversubscribed Series D funding round to advance the clinical development of an experimental vaccine designed to help prevent cancer in people with Lynch syndrome.

The financing was co-led by M Ventures and Revelation Partners, with participation from new investors including Angelini Investments, the European Investment Bank through its Aurea co-investment facility with Angelini Ventures, and Neva SGR. Existing investors also participated in the round.

Nouscom plans to use the funding to support a global clinical trial of NOUS-209, an investigational vaccine intended to train the immune system to recognise cancer-associated targets before tumours develop.

The investment highlights continued European biotech interest in treatments that could move healthcare beyond responding to established disease and towards preventing some cancers from developing.

Understanding Lynch syndrome

Lynch syndrome is an inherited genetic condition associated with an increased lifetime risk of several cancers, particularly colorectal and endometrial cancer.

People with the condition often require regular medical surveillance and may consider preventive interventions based on their individual risk and medical advice. The level of risk varies, and management decisions depend on the person’s circumstances.

Despite advances in screening and treatment, inherited cancer-risk conditions remain an important area of medical research. Scientists are investigating whether the immune system can be trained to recognise abnormal cells early enough to prevent some cancers from progressing.

This is the research question behind Nouscom’s NOUS-209 programme.

How the experimental vaccine works

NOUS-209 is designed as an off-the-shelf therapeutic vaccine targeting shared cancer-associated markers known as frameshift neoantigens.

These markers can arise when certain genetic changes alter the proteins produced by cells. The vaccine aims to stimulate T cells, a type of immune cell, to recognise these targets and attack cells that display them.

Because the programme targets markers shared by multiple people with Lynch syndrome, the approach is intended to avoid the need to design a completely individualised vaccine for every participant.

The strategy could potentially make production and delivery more practical than approaches that must be developed separately for each patient. However, whether the vaccine can prevent cancer in clinical practice remains an open scientific question.

An experimental vaccine must demonstrate not only that it produces an immune response, but also that it provides a meaningful clinical benefit and has an acceptable safety profile.

What early research has shown

Nouscom has reported encouraging early findings from a Phase 1b/2 study involving healthy people with Lynch syndrome.

According to Tech Funding News, 45 participants received an initial dose followed by a booster eight weeks later. All 37 participants whose immune responses could be evaluated showed a response against the targeted neoantigens. The company also reported that these responses remained detectable after one year in 85% of the evaluable participants.

These findings provide evidence that the vaccine can stimulate the intended immune response in the studied group.

However, an immune response is not the same as proof that cancer has been prevented. The early study did not include a control group, making it difficult to determine how the observed results compare with what would have happened without vaccination.

The larger clinical trial will therefore be important in assessing whether the approach can produce meaningful benefits for people at elevated inherited cancer risk.

The US Food and Drug Administration granted NOUS-209 Fast Track designation in June 2026, according to the report. This designation is intended to facilitate the development and review of medicines addressing serious conditions with significant unmet medical needs. It does not mean that the vaccine has been approved.

Why investors are backing the programme

Developing a new medicine requires substantial investment in research, clinical testing, manufacturing and regulatory preparation.

The $135 million funding round gives Nouscom resources to advance a larger trial intended to support a potential future regulatory application.

The round also reflects investor interest in cancer immunotherapy and prevention strategies. Although many established cancer treatments aim to treat tumours after they appear, preventive approaches could offer a different option for people whose inherited conditions place them at increased risk.

The investment group includes biotechnology-focused investors and organisations supporting European innovation. Their participation provides financial support for a programme that still has significant scientific and regulatory milestones ahead.

For the wider European biotech sector, the financing illustrates how private capital and institutional investment can help move research from early clinical studies towards larger trials.

The challenges ahead

NOUS-209 still needs to demonstrate that it can reduce cancer incidence or deliver another clinically meaningful benefit, while maintaining an acceptable safety profile.

The next trial will need to provide stronger evidence about effectiveness, duration of protection and the patients most likely to benefit. Researchers and regulators will also need to assess how vaccination might fit alongside existing screening and preventive care.

These questions are especially important because people with Lynch syndrome already have established surveillance options. An experimental vaccine would need to be evaluated carefully before it could be considered a replacement for, or addition to, current clinical management.

The programme’s progress will depend on the quality of the evidence generated in future studies rather than the amount of funding raised alone.

A potential new direction for cancer prevention

Nouscom’s latest investment gives the company the opportunity to test whether a shared-target vaccine can help prevent cancer in people with an inherited predisposition.

If future trials demonstrate a meaningful benefit, the approach could represent an important development in cancer prevention. For now, the results remain preliminary, and the vaccine should be regarded as experimental.

The funding nevertheless highlights the role of biotechnology innovation in addressing complex medical challenges. By combining immunology, clinical research and substantial investment, Nouscom is working towards a goal that researchers have pursued for years: identifying ways to intervene before cancer takes hold.